ClinicalTrials.Veeva

Menu

High Resolution Optical Coherence Tomography

I

Insel Gruppe AG, University Hospital Bern

Status

Enrolling

Conditions

Optic Nerve Diseases
Retinal Dystrophy
Retinal Neovascularization
Retinal Artery Occlusion
Retinal Detachment
Macular Edema
Macular Disease
Retinal Disease
Retinal Edema
Hypertensive Retinopathy
Uveitis
Macular Degeneration
Diabetic Macular Edema
Glaucoma
Retinal Vein Occlusion
Diabetic Retinopathy

Treatments

Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)

Study type

Observational

Funder types

Other

Identifiers

NCT05130385
High Res OCT
2021-D0038 (Registry Identifier)

Details and patient eligibility

About

Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases

Full description

The high resolution optical coherence tomography (High-Res-OCT) is an improvement of a non-invasive routinely used imaging technique, the optical coherence tomography (OCT), with a light-source capable of providing an increased axial resolution. The routinely used Spectral-Domain OCT has a center wavelength of 880 nm and a spectral bandwidth of 40 nm, resulting in an axial resolution of approximately 7 μm in the eye and is used routinely worldwide. The High-Res OCT works with a central wavelength of 840 nm and an increased bandwidth of 130 nm, making it possible to improve the optical axial resolution in tissue from 7 to 3 µm, without increasing the maximum laser exposure limit. The improved axial resolution of the High-Res OCT results in clearer and more detailed images. The technique is routinely used in clinical practice and the device used for High-Res-OCT (Heidelberg, SPECTRALIS® High-Res OCT- DMR001) has received CE mark (european conformity in the extended Single Market in the European Economic Area) approval in March 2021. We plan to compare High-Res-OCT as an imaging modality to conventional imaging modalities used in clinical routine, such as the Spectral-Domain-OCT (SD-OCT)

Enrollment

550 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients from the Department of Ophthalmology, University Hospital Bern requiring conventional imaging for eye disease and willing to sign informed consent Patients of 18 years or older

Exclusion criteria

  • Patients not willing or able to sign informed consent
  • Patients younger than 18 years
  • Patients with epilepsy.
  • Vulnerable subjects (except the objectives of the investigation concern vulnerable subjects specifically),
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
  • Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
  • Enrolment of the PI, his/her family members, employees and other dependent persons

Trial design

550 participants in 10 patient groups

Diabetic Retinopathy
Description:
Patients with various degree of diabetic retinopathy
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Artery and vein occlusion
Description:
Patients with history of artery or vein occlusion (central or branch artery)
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Glaucoma
Description:
Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma)
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Optic nerve neuropathy
Description:
Patients with history of various optic nerve neuropathies
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Hereditary retinal diseases
Description:
Patients with history of various retinal dystrophies
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Retinal detachment
Description:
Patients history of retinal detachment
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Age related macular degeneration
Description:
Patients with history of age related macular degeneration
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Retinal changes from arterial hypertension
Description:
Patients with history of arterial hypertension
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Uveitis
Description:
Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)
Healthy
Description:
Healthy age matched control subjects
Treatment:
Device: Standard spectral domain OCT (SD-OCT)
Device: High-resolution optical coherence tomography (High-Res-OCT)

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Martin S Zinkernagel, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems